Therapies in development. Overview by Kevin McFarthing.

Kevin McFarthing: “I was diagnosed with Parkinson’s in 2012.  As a scientist, I tried to find out as much as I could about the condition.  Part of that was to investigate potential therapies that may be of benefit in the future.  This resulted in an ad ho list that needed organising in a spreadsheet.  Following lots of […]

Read More

Interview With CEO Of The Michael J. Fox Foundation Dr. Todd Sherer

The following first appeared on tmrwedition.   Todd Sherer, PhD, is the Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research (MJFF). MJFF is the largest nonprofit funder of Parkinson’s disease research in the world, investing more than $750 million in research to date. Dr. Sherer directs MJFF’s research strategy and is responsible for the […]

Read More

British Medical Journal. Ben Stecher et al: Research into Parkinson’s Disease needs reform

“As Parkinson’s Disease (PD) patients and research advocates, we remain hopeful that the whirlwind of research and translational studies which flood the pages of journals around the world will result in treatments that significantly improve quality of life for people with PD within our lifetime. While the Parkinson’s community continues to wait, however, we must […]

Read More

Interview with Neurodegeneration Specialist Prof. Patrik Brundin

The following first appeared on tmrwedition. Prof. Patrik Brundin leads the Center for Neurodegenerative Science at Van Andel Research Institute where his research team is focused on experimental models and novel therapies in Parkinson’s disease. Dr. Brundin is one of the most cited scientists in neurodegenerative diseases, with a focus on Parkinson’s, and has received numerous […]

Read More